Compare COFS & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COFS | ADCT |
|---|---|---|
| Founded | 1898 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 443.5M | 484.4M |
| IPO Year | 1995 | 2019 |
| Metric | COFS | ADCT |
|---|---|---|
| Price | $30.23 | $4.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $36.00 | $7.75 |
| AVG Volume (30 Days) | 59.9K | ★ 865.9K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ 2.01 | N/A |
| Revenue | ★ $227,624,000.00 | $81,357,000.00 |
| Revenue This Year | $22.13 | N/A |
| Revenue Next Year | $4.47 | $66.49 |
| P/E Ratio | $15.00 | ★ N/A |
| Revenue Growth | ★ 63.64 | 14.85 |
| 52 Week Low | $26.10 | $1.23 |
| 52 Week High | $33.58 | $4.98 |
| Indicator | COFS | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 53.14 |
| Support Level | $28.37 | $3.93 |
| Resistance Level | $30.76 | $4.71 |
| Average True Range (ATR) | 1.07 | 0.26 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 65.20 | 47.06 |
ChoiceOne Financial Services Inc is a full-service banking institution. It is engaged in the business of providing personal and business banking solutions, borrowing solutions, and treasury notes and bonds services. The bank's product and services portfolio consist of time, savings and demand deposits, safe deposit services, automated transaction machine services, commercial and consumer loans, commercial lending to business, industry, agricultural, construction, inventory, and real estate categories. Its primary market area is Kent, Muskegon, Newaygo, and Ottawa counties in western Michigan, and Lapeer, Macomb, and St. Clair counties in southeastern Michigan in the communities where the Bank's respective offices are located.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).